Silicone layer in glass primary packaging: stability and optimization through a combined approach of mathematical modeling and experimental DOEs
Abizer Harianawala, SG US TEC site Leader
Danilo Donato, Advanced Technology Analyst, SG Lab Advanced Technology
Chiara De Zorzi, Research Scientist, SG Lab Analytics
The achievement of a proper silicone layer formation on glass primary packaging is crucial in developing robust parenteral/device/combination products that are stable during their shelf life and delivery to the patient.
This webinar will focus on optimizing the silicone spraying process on glass barrels by combining a mathematical modeling approach and experimental data. We will share our DOE approach to optimize the silicone spraying process, the mathematical model, and experimental results. We will also discuss outcomes on silicon layer stability.
Finally, we will present an overview of analytical capabilities in terms of silicon layer characterization and performance, focusing on customized case studies.
Key takeaways from this event include:
- Siliconization characterization: techniques and case studies
- DOE approach to optimize silicone layer
- Mathematical model: matching experimental data to describe silicone spraying process
- Study on silicone layer stability
About the Sponsors
Established in 1949, Stevanato Group is the world’s largest, privately-owned designer and producer of glass primary packaging for the pharmaceutical industry. From its outset, the Group has developed its own glass converting technology to ensure the highest standards of quality. The Group comprises a wide set of capabilities dedicated to serving the biopharmaceutical and diagnostic industries: from glass containers with its historic brand Ompi, to high-precision plastic diagnostic and medical components, to contract manufacturing for drug delivery devices, to vision inspection systems, assembly, and packaging equipment.
The Group also provides analytical and testing services to study container closure integrity and integration into drug delivery devices, streamlining the drug development process. Thanks to its unique approach as a one-stop-shop, Stevanato Group can offer a unique set of solutions to biopharma companies for a faster time to market and a reduced total cost of ownership.